Last reviewed · How we verify
NCT00418899
Gliogene: Brain Tumor Linkage Study
trial testing Questionnaire in Brain Tumor in 17,080 participants. Status unknown.
1 September 2022
Quick facts
| Lead sponsor | M.D. Anderson Cancer Center |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 17,080 |
| Start date | 12 February 2004 |
| Primary completion | 1 September 2022 |
| Estimated completion | 1 September 2022 |
| Sites | 15 locations across Denmark, Finland, Sweden, United Kingdom, Israel, United States |
Drugs / interventions tested
- Questionnaire
Conditions studied
- Brain Tumor — all drugs for Brain Tumor →
- Glioma — all drugs for Glioma →
Sponsor
M.D. Anderson Cancer Center — full company profile →
Who can join
Eligibility, any sex, with Brain Tumor or Glioma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this research study is to investigate the role of genes that may point to a higher risk of developing a glioma. Researchers will use new gene mapping techniques to study how high-risk factors are passed on through a family's genes and increase the risk of developing gliomas. Objectives: We propose an international multi-center, multidisciplinary study consortium, GLIOGENE, to identify susceptibility genes in high-risk familial brain tumor pedigrees using the most sophisticated genetic analysis methods available. To address our hypothesis, we propose the following specific aims: Aim 1: Establish a cohort of 400 high-risk pedigrees for genetic linkage analysis. To date, we have identified and collected biologic samples from 20 high-risk families that have met our criteria of 2 or more relatives diagnosed with a brain tumor. From the 15 centers in the United States and Europe, we will screen and obtain epidemiologic data from approximately 17,080 gliomas cases to identify a target of 400 families for genetic analysis. We will establish a cohort of the first and second-degree relatives from these glioma cases to obtain new knowledge about how cancer aggregates in glioma families. We will also acquire biospecimens (blood and tumor tissue), and risk factor data from relevant family members. Aim 2: Identify candidate regions linked to familial brain tumors. To strengthen evidence of linkage to regions found in our preliminary analysis and to identify additional regions linked to brain tumors, we will genotype informative glioma pedigrees identified in aim 1 using Affymetrix 10K GeneChip with markers spaced throughout the genome, and conduct a genome-wide multipoint linkage scan with these markers. Aim 3: Fine map the regions established in Aim 2 by genotyping selected SNPs from genome databases. We will attempt to further refine the regions identified in Aim 2 to less than 1cM by using approximately 1,500 - 2,000 carefully selected SNPs. The prioritization of regions will be based on a combination of the strength of evidence for linkage from families of various ethnic backgrounds and the presence of obvious candidate genes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT00418899
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Questionnaire
Trials testing the same drug.
- NCT04466371 — Perceptions of Undergraduate Students and Teaching Staff on Online Teaching · suspended
- NCT07089953 — Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits: a Randomiz · NA · not yet recruiting
- NCT07418775 — Tumor Genomics, Individual Risk Factors, and External Drivers of Health on Health Outcomes for Patients With Meningioma · not yet recruiting
- NCT07226804 — Nanosecond Pulsed Field Ablation in the Management of Benign Thyroid Nodules · not yet recruiting
- NCT07532954 — The Impact Of A Patient Support Community On Patients With Neuroendocrine Cervical Cancer: NECC Peer Support · recruiting
Other recruiting trials for Brain Tumor
Currently open trials in the same condition.
- NCT07224503 — C-SMART vs BE Well for Patients With Brain Tumors · NA · recruiting
- NCT07323966 — Feasibility of Mask-Free Radiotherapy for Brain Tumor Patients · NA · recruiting
- NCT07122752 — Feasibility and Outcomes of 3D-printed External Cranial Orthosis After Craniectomy · active not recruiting
- NCT07105358 — Visual Plasticity Following Brain Lesions · NA · recruiting
- NCT06810544 — Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss · Phase 1, PHASE2 · recruiting
Other M.D. Anderson Cancer Center trials
Trials by the same sponsor.
- NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
- NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
- NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
- NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
- NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00418899 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
- Last refreshed: 31 December 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00418899.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing